Skip to main content
. 2021 Sep 21;17(14):3936–3953. doi: 10.7150/ijbs.63732

Figure 3.

Figure 3

Lrp6 haploinsufficiency (Lrp6(+/-)) affected the therapeutic effect of silibinin in NAFLD mice. (A) Comparison of the liver function, as determined from the levels of enzymatic markers, and liver/body weight ratio between the Lrp6(+/+) and the Lrp6(+/-) mice received MCD diet with and without the treatment of silibinin. (B) Change of the liver function and liver/body weight ratio by silibinin treatment between the Lrp6(+/+) and Lrp6(+/-) mice. * P < 0.05; NS, No significance.